Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (19)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Shah, A.
Right arrow Articles by Heller, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shah, A.
Right arrow Articles by Heller, A. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1994) 33, 795-801
© 1994 The British Society for Antimicrobial Chemotherapy

other

Comparative pharmacokinetics and safety of ciprofloxacin 400 mg iv thrice daily versus 750 mg po twice daily

A. Shah, J. Lettieri, L. Kaiser, R. Echols and A. H. Heller

Miles Inc., Pharmaceutical Division 400 Morgan Lane, West Haven, Connecticut 06516, USA

Received 2 September 1993; accepted 20 November 1993

Comparative pharmacokinetics of iv and oral ciprofloxacin was studied in 24 healthy male subjects given 400 mg iv tds or 750 mg po bd in a randomized, doubleblind, placebo controlled, crossover fashion with at least a 10 day washout period. Blood and urine samples were obtained following the first (single dose) and last (steady state) dose in each treatment period. After single dosing and under steady state conditions, the calculated 24 h area under the serum concentration versus time curve, (AUC0–24) after 400 mg iv tds (AUC0–8 x 3) was equivalent to the AUC0–24 after 750 mg po bd (AUC0–12 x 2). Peak serum concentrations produced by the iv regimen were very similar to those observed after the 750 mg oral dose. The extent of accumulation was similar following either dosing regimen and was approximately 35%. Overall, the incidence of adverse effects (none of which was serious) was higher with the iv regimen than with the oral regimen, mainly due to injection site reaction, which was the most commonly reported adverse event.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
C. R. Frei, N. P. Wiederhold, and D. S. Burgess
Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation
J. Antimicrob. Chemother., March 1, 2008; 61(3): 621 - 628.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
P. Dupont, D. Hocquet, K. Jeannot, P. Chavanet, and P. Plesiat
Bacteriostatic and bactericidal activities of eight fluoroquinolones against MexAB-OprM-overproducing clinical strains of Pseudomonas aeruginosa
J. Antimicrob. Chemother., April 1, 2005; 55(4): 518 - 522.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. J. Campion, P. J. McNamara, and M. E. Evans
Evolution of Ciprofloxacin-Resistant Staphylococcus aureus in In Vitro Pharmacokinetic Environments
Antimicrob. Agents Chemother., December 1, 2004; 48(12): 4733 - 4744.
[Abstract] [Full Text] [PDF]

Home page
 Am J Sports MedHome page
R. J. Williams III, E. Attia, T. L. Wickiewicz, and J. A. Hannafin
The Effect of Ciprofloxacin On Tendon, Paratenon, and Capsular Fibroblast Metabolism
Am. J. Sports Med., May 1, 2000; 28(3): 364 - 369.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
W. V. Kern, A. Cometta, R. de Bock, J. Langenaeken, M. Paesmans, H. Gaya, G. Zanetti, T. Calandra, M. P. Glauser, F. Crokaert, et al.
Oral versus Intravenous Empirical Antimicrobial Therapy for Fever in Patients with Granulocytopenia Who Are Receiving Cancer Chemotherapy
N. Engl. J. Med., July 29, 1999; 341(5): 312 - 318.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. Lipman, J. Scribante, A. G. S. Gous, H. Hon, S. Tshukutsoane, and The Baragwanath Ciprofloxacin Study Group
Pharmacokinetic Profiles of High-Dose Intravenous Ciprofloxacin in Severe Sepsis
Antimicrob. Agents Chemother., September 1, 1998; 42(9): 2235 - 2239.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.